Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Essex Woodlands leads $40.4mm Series C round for Catalyst

Executive Summary

First-time investor Essex Woodlands led the $40.4mm Series C financing for Catalyst Biosciences (redesigns proteases--called Alterases--that target disease-causing proteins). Returning backers Burrill & Co., HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures, and Sofinnova Ventures also participated. A managing director from Essex joined the company's board. Catalyst says it will now have enough money to support its activities for the next few years, including moving its CB813 Factor VIIa treatment for hemophilia (currently at the preclinical stage) through Phase I/II proof-of-concept studies.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies